Colorectal most cancers (CRC) is the third most identified most cancers worldwide. Progesterone is related to a decreased danger of CRC and results in a beneficial prognosis. Nonetheless, the precise mechanism by which progesterone suppresses malignant development stays to be elucidated. Within the current research, the extent of progesterone was first analysed in 77 sufferers with CRC, and immunohistochemistry was carried out to detect the expression of progesterone receptor (PGR) within the paired specimens. The correlations between progesterone, PGR and CRC prognosis had been assessed. A Cell Counting Package‑eight assay was then used to detect proliferation of the CRC cells. Circulation cytometry was carried out to estimate apoptosis and to guage the cycle of the CRC cells.
A xenograft tumour mannequin was established in nude mice to evaluate the function of progesterone in tumour development. Lastly, a PCR microarray was used to display screen differentially expressed genes to additional interpret the mechanism by which progesterone inhibits the malignant development of CRC. It was discovered that low expression of progesterone and PGR had been considerably related to poor prognosis of CRC. As well as, progesterone suppressed CRC cell proliferation by arresting the cell cycle and inducing apoptosis in vitro. Furthermore, the inhibitory function of progesterone in tumour development was verified in vivo.
Additional investigation confirmed that the extent of development arrest and DNA harm‑inducible protein α (GADD45α) was up‑regulated by progesterone, and this was adopted by the activation of the JNK pathway. Progesterone elevated the exercise of the JNK pathway through GADD45α to inhibit proliferation by arresting the cell cycle and inducing apoptosis, thereby suppressing the malignant development of CRC. Subsequently, it may be concluded that progesterone and PGR may act as inhibiting elements for poor prognosis of CRC.
Decide the incremental yield of subsequent technology sequencing (predominantly exome sequencing (ES)) over quantitative fluorescence-polymerase chain response (QF-PCR) and chromosome microarray evaluation (CMA)/karyotyping in; (i) all instances of prenatally identified non-immune hydrops fetalis (NIHF); (ii) remoted NIHF; (iii) NIHF related to further structural anomalies and; (iv) NIHF in line with severity (i.e., two cavities versus three or extra cavities affected).
MiRNA expression profiling and emergence of latest prognostic signature for oral squamous cell carcinoma
Oral squamous cell carcinoma (OSCC), the commonest sort of head and neck cancers, is related to excessive recurrence, metastasis, low long-term survival charges and poor remedy consequence. As deregulated miRNA expression performs an important function in malignant transformation and most cancers development, the current research is aimed toward profiling the miRNA expression sample in OSCC and creating a brand new miRNA prognostic signature for oral most cancers. MiRNA expression profiling was carried out utilizing MiRNA microarray in 30 tumor and 18 regular samples. MiRNA signature obtained was validated with quantitative actual time PCR (qRT-PCR) in 144 tumor and 36 regular samples.
The potential targets, scientific implications and prognostic worth of the miRNA signature had been elucidated by numerous bioinformatics and statistical analyses. Microarray profiling recognized a set of 105 miRNAs to be differentially expressed in OSCC, out of which a subset of 19 most dysregulated miRNAs had been validated by qRT-PCR. In silico evaluation revealed the signature miRNAs to be concerned in numerous most cancers related pathways. Up-regulation of miR-196a, miR-21, miR-1237 and downregulation of miR-204, miR-144 was related to poor prognosis of OSCC sufferers. The mir-196a/miR-204 expression ratio emerged as finest predictor for illness recurrence and affected person survival. Altogether, our research recognized a miRNA signature for OSCC with prognostic significance.
Identification of fibroblast activation-related genes in two acute kidney harm fashions
Ischemia-reperfusion harm and drug-induced nephrotoxicity are the 2 most typical causes for acute kidney harm (AKI). Nonetheless, little consideration has been paid to early activation of fibroblasts within the development of AKI to persistent kidney illness (CKD). The current research aimed to determine associated genes and pathways on fibroblast activation in two mouse fashions of AKI: ischemia-reperfusion harm (IRI) mannequin and folic acid (FA)-induced harm mannequin. The microarray expression profiles of GSE62732 and GSE121190 had been downloaded from the GEO database, and the differentially expressed genes (DEGs) was analyzed utilizing the Limma bundle of R software program.
Principal element evaluation (PCA) was additionally carried out utilizing R. The practical info of gene merchandise was annotated by Gene Ontology (GO) and DAVID on-line database, and the pathway evaluation was carried out through the use of the Kyoto Encyclopedia of Genes and Genomes pathway (KEGG) database. Protein-protein interactions (PPI) community was constructed by STRING and Cytoscape. Moreover, within the Hypoxia/Reoxygenation (H/R) mannequin, the morphological adjustments of cells had been noticed beneath microscope and the expression of the hub genes in NRK-49F cells had been validated by qRT-PCR assays. A complete of 457 DEGs had been recognized.
Alpha-bungarotoxin, CF640r |
|||
| 9-00004 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
Alpha-bungarotoxin, CF488a |
|||
| 9-00005 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-bungarotoxin CF488a |
|||
| 9-00005 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
Alpha-bungarotoxin, CF568 |
|||
| 9-00006 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-bungarotoxin, CF568 |
|||
| 9-00006 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
Alpha-bungarotoxin, CF594 |
|||
| 9-00007 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-bungarotoxin CF594 |
|||
| 9-00007 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
Alpha-bungarotoxin, CF633 |
|||
| 9-00009 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-bungarotoxin, CF633 |
|||
| 9-00009 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
Alpha-bungarotoxin |
|||
| 00010-1 | Biotium | 1MG | EUR 168 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
Fluorescein-Alpha-bungarotoxin |
|||
| 00011 | Biotium | 500uG | EUR 367 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Tetramethylrhodamine-Alpha-bungarotoxin |
|||
| 00012 | Biotium | 500uG | EUR 383 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Fluorescein-alpha-bungarotoxin: (10x50ug) |
|||
| 00013 | Biotium | 10ST | EUR 417 |
|
Description: Minimum order quantity: 1 unit of 10ST |
|||
Tetramethylrhodamine-alpha-bungarotoxin: (10x50ug) |
|||
| 00014 | Biotium | 10ST | EUR 466 |
|
Description: Minimum order quantity: 1 unit of 10ST |
|||
Sulforhodamine 101-a-bungarotoxin (Texas Red--a-bungarotoxin): (500ug) |
|||
| 00015 | Biotium | 500uG | EUR 466 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Sulforhodamine 101-a-bungarotoxin (Texas Red--a-bungarotoxin): (10x50ug) |
|||
| 00016 | Biotium | 10ST | EUR 523 |
|
Description: Minimum order quantity: 1 unit of 10ST |
|||
Biotin-xx-a-bungarotoxin |
|||
| 00017 | Biotium | 500uG | EUR 433 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-Bungarotoxin, CF555 conjugate |
|||
| 9-00018 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-Bungarotoxin, CF555 conjugate |
|||
| 9-00018 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Biotin-cAMP, diisopropylethylammonium salt: |
|||
| 00020 | Biotium | 1MG | EUR 314 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
Biotin-cAMP, diisopropylethylammonium salt: (20x50ug) |
|||
| 00020-1 | Biotium | 20ST | EUR 418 |
|
Description: Minimum order quantity: 1 unit of 20ST |
|||
Biotin-cGMP, diisopropylethylammonium salt: |
|||
| 00021 | Biotium | 1MG | EUR 344 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
Biotin-cGMP, diisopropylethylammonium salt: (20x50ug) |
|||
| 00021-1 | Biotium | 20ST | EUR 448 |
|
Description: Minimum order quantity: 1 unit of 20ST |
|||
Cyanine 644-cAMP: |
|||
| 00022 | Biotium | 1MG | EUR 491 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
Cyanine 644-cAMP: (20x50ug) |
|||
| 00022-1 | Biotium | 20ST | EUR 625 |
|
Description: Minimum order quantity: 1 unit of 20ST |
|||
Fluorescein Methotrexate, triammonium salt: |
|||
| 00023 | Biotium | 1MG | EUR 281 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
Staurosporine |
|||
| 00025 | Biotium | 100uG | EUR 139 |
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
Alpha-bungarotoxin, CF543 |
|||
| 00026 | Biotium | 500uG | EUR 494 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Rhodamine phalloidin 300u |
|||
| 00027 | Biotium | 300 | EUR 345 |
|
Description: Minimum order quantity: 1 unit of 300 |
|||
Biotin-xx-phalloidin |
|||
| 00028 | Biotium | 100U | EUR 428 |
|
Description: Minimum order quantity: 1 unit of 100U |
|||
Fluorescein-phalloidin |
|||
| 00030 | Biotium | 300U | EUR 345 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Rhodamine 110 phalloidin |
|||
| 00032 | Biotium | 300ST | EUR 345 |
|
Description: Minimum order quantity: 1 unit of 300ST |
|||
Sulforhodamine 101 (Texas-Red) Phalloidin |
|||
| 00033 | Biotium | 300EU | EUR 345 |
|
Description: Minimum order quantity: 1 unit of 300EU |
|||
Phalloidin, CF405M |
|||
| 00034 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF405M |
|||
| 00034-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
CF488A-cAMP |
|||
| 00036 | Biotium | 100ug | EUR 172 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
CF640R-cAMP |
|||
| 00037 | Biotium | 100ug | EUR 172 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Phalloidin, CF555 |
|||
| 00040 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF555 |
|||
| 00040-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF647 |
|||
| 00041 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF647 |
|||
| 00041-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF488A |
|||
| 00042 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF488A |
|||
| 00042-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF543 |
|||
| 00043 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF543 |
|||
| 00043-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF568 |
|||
| 00044 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF568 |
|||
| 00044-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF594 |
|||
| 00045 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF594 |
|||
| 00045-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF633 |
|||
| 00046 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF633 |
|||
| 00046-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF660R |
|||
| 00047 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF660R |
|||
| 00047-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF680R |
|||
| 00048 | Biotium | 300U | EUR 466 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF680R |
|||
| 00048-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF350 |
|||
| 00049 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF350 |
|||
| 00049-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF640R |
|||
| 00050 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF640R |
|||
| 00050-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF532 |
|||
| 00051 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF532 |
|||
| 00051-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF660C |
|||
| 00052 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF660C |
|||
| 00052-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF680 |
|||
| 00053 | Biotium | 300U | EUR 466 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF680 |
|||
| 00053-T | Biotium | 50U | EUR 147 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF430 |
|||
| 00054 | Biotium | 300U | EUR 449 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF430 |
|||
| 00054-T | Biotium | 50U | EUR 139 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF440 |
|||
| 00055 | Biotium | 300U | EUR 449 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF440 |
|||
| 00055-T | Biotium | 50U | EUR 139 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Cholera Toxin Subunit B, CF488A conjugate |
|||
| 00070 | Biotium | 100ug | EUR 261 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF568 conjugate |
|||
| 00071 | Biotium | 100ug | EUR 261 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF594 conjugate |
|||
| 00072 | Biotium | 100ug | EUR 261 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF640R conjugate |
|||
| 00073 | Biotium | 100ug | EUR 264 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF532 conjugate |
|||
| 00074 | Biotium | 100ug | EUR 264 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF543 conjugate |
|||
| 00075 | Biotium | 100ug | EUR 264 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF620R conjugate |
|||
| 00076 | Biotium | 100ug | EUR 264 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF633 conjugate |
|||
| 00077 | Biotium | 100ug | EUR 264 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF660R conjugate |
|||
| 00078 | Biotium | 100ug | EUR 264 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF680R conjugate |
|||
| 00079 | Biotium | 100ug | EUR 282 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Human Transferrin, CF488A conjugate |
|||
| 00081 | Biotium | 1mg | EUR 149 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
Human Transferrin, CF543 conjugate |
|||
| 00082 | Biotium | 1mg | EUR 149 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
Human Transferrin, CF568 conjugate |
|||
| 00083 | Biotium | 1mg | EUR 149 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
Human Transferrin, CF594 conjugate |
|||
| 00084 | Biotium | 1mg | EUR 149 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
Human Transferrin, CF640R conjugate |
|||
| 00085 | Biotium | 1mg | EUR 149 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
Human Transferrin, CF680R conjugate |
|||
| 00086 | Biotium | 1mg | EUR 149 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
Human Transferrin, CF750 conjugate |
|||
| 00087 | Biotium | 1mg | EUR 155 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
HIV-1 tat recombinant antigen |
|||
| 00110-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HIV-1 tat recombinant antigen full length 15 kDa |
|||
HIV-1 tat recombinant antigen |
|||
| 00110-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HIV-1 tat recombinant antigen full length 15 kDa |
|||
HIV-1 GAG P24 Recombinant Antigen |
|||
| 00111-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
|||
HIV-1 GAG P24 Recombinant Antigen |
|||
| 00111-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
|||
HIV-1 nef recombinant antigen |
|||
| 00112-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
|||
HIV-1 nef recombinant antigen |
|||
| 00112-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
|||
HIV-1 env gp41 recombinant antigen |
|||
| 00113-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa |
|||
HIV-1 env gp41 recombinant antigen |
|||
| 00113-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa |
|||
HIV-2 GP 36 Recombinant Antigen |
|||
| 00114-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa |
|||
HIV-2 GP 36 Recombinant Antigen |
|||
| 00114-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa |
|||
HCV core recombinant antigen |
|||
| 00115-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa |
|||
HCV core recombinant antigen |
|||
| 00115-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa |
|||
HCV core recombinant antigen, Biotin conjugate |
|||
| 00115-V-B-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Biotin conjugate. |
|||
HCV core recombinant antigen, Biotin conjugate |
|||
| 00115-V-B-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Biotin conjugate. |
|||
HCV core recombinant antigen, FITC conjugate |
|||
| 00115-V-F-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Fluorescein conjugate. |
|||
HCV core recombinant antigen, FITC conjugate |
|||
| 00115-V-F-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Fluorescein conjugate. |
|||
HCV core recombinant antigen, Rhodamine |
|||
| 00115-V-R-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa . Rhodamine conjugate. |
|||
HCV core recombinant antigen, Rhodamine |
|||
| 00115-V-R-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa . Rhodamine conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b |
|||
| 00116-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. |
|||
HCV NS4 recombinant antigen NS4a+b |
|||
| 00116-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. |
|||
HCV NS4 recombinant antigen NS4a+b, Biotin |
|||
| 00116-V-B-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Biotin conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b, Biotin |
|||
| 00116-V-B-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Biotin conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b, FITC |
|||
| 00116-V-F-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Fluorescein conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b, FITC |
|||
| 00116-V-F-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Fluorescein conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b, Rhodamine |
|||
| 00116-V-R-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Rhodamine conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b, Rhodamine |
|||
| 00116-V-R-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Rhodamine conjugate. |
|||
HCV NS3 recombinant antigen |
|||
| 00117-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS3 recombinant antigen a.a 1400 to a.a 1643 of HCV polyprotein 22 kDa |
|||
HCV NS3 recombinant antigen |
|||
| 00117-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS3 recombinant antigen a.a 1400 to a.a 1643 of HCV polyprotein 22 kDa |
|||
HBV core recombinant antigen |
|||
| 00120-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 183 of HBV core antigen 18 kDa |
|||
HBV core recombinant antigen |
|||
| 00120-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 183 of HBV core antigen 18 kDa |
|||
HBV core recombinant antigen, Delta |
|||
| 00121-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 144 of HBV core antigen 16 kDa |
|||
HBV core recombinant antigen, Delta |
|||
| 00121-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 144 of HBV core antigen 16 kDa |
|||
HBV surface recombinant antigen HBsAg |
|||
| 00122-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant |
|||
HBV surface recombinant antigen HBsAg |
|||
| 00122-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant |
|||
HBV surface recombinant antigen HBsAg antigen |
|||
| 00123-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant High purity |
|||
HBV surface recombinant antigen HBsAg antigen |
|||
| 00123-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant High purity |
|||
HBV surface recombinant antigen HBsAg antigen |
|||
| 00124-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HBV surface recombinant antigen HBsAg antigen 31 kDa E. coli recombinant |
|||
HBV surface recombinant antigen HBsAg antigen |
|||
| 00124-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HBV surface recombinant antigen HBsAg antigen 31 kDa E. coli recombinant |
|||
HEV (Birma) ORF2 recombinant antigen |
|||
| 00131-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 633 to a.a 659. |
|||
HEV (Birma) ORF2 recombinant antigen |
|||
| 00131-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 633 to a.a 659. |
|||
HEV (Birma) ORF2 recombinant antigen |
|||
| 00132-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 403 to a.a 461. |
|||
HEV (Birma) ORF2 recombinant antigen |
|||
| 00132-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 403 to a.a 461. |
|||
AA 403-461 HEV Birma ORF2 Recombinant Antigen |
|||
| 00133-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 92 to a.a 123. |
|||
AA 403-461 HEV Birma ORF2 Recombinant Antigen |
|||
| 00133-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 92 to a.a 123. |
|||
T, Pallidum recombinant antigen p15 |
|||
| 00141-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: T. Pallidum recombinant antigen p15 (full length) |
|||
T, Pallidum recombinant antigen p15 |
|||
| 00141-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: T. Pallidum recombinant antigen p15 (full length) |
|||
T, Pallidum recombinant antigen p17 |
|||
| 00142-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: T. Pallidum recombinant antigen p17 (full length) |
|||
T, Pallidum recombinant antigen p17 |
|||
| 00142-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: T. Pallidum recombinant antigen p17 (full length) |
|||
T, Pallidum recombinant antigen p45 |
|||
| 00143-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: T. Pallidum recombinant antigen p45 (full length) |
|||
T, Pallidum recombinant antigen p45 |
|||
| 00143-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: T. Pallidum recombinant antigen p45 (full length) |
|||
T, pallidum recombinant antigen TmpA |
|||
| 00144-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: T. Pallidum recombinant antigen TmpA (full length) |
|||
T, pallidum recombinant antigen TmpA |
|||
| 00144-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: T. Pallidum recombinant antigen TmpA (full length) |
|||
HCV core 2-119aa recombinant antigen |
|||
| 00150-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV core 2-119aa recombinant antigen. Genotypes available: 1a, 1b, 2a, 2b, 3a, 3b, 3/10, 4, 5, 6a |
|||
HCV core 2-119aa recombinant antigen |
|||
| 00150-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV core 2-119aa recombinant antigen. Genotypes available: 1a, 1b, 2a, 2b, 3a, 3b, 3/10, 4, 5, 6a |
|||
HCV Core 24 Antigen |
|||
| 00151-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV core 24 antigen. |
|||
HCV Core 24 Antigen |
|||
| 00151-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV core 24 antigen. |
|||
HCV core recombinant antigen |
|||
| 00152-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV core recombinant antigen a.a.105-302 |
|||
HCV core recombinant antigen |
|||
| 00152-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV core recombinant antigen a.a.105-302 |
|||
HCV NS3 1192-1456 aa Recombinant Antigen |
|||
| 00153-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS3 1192-1456aa recombinant antigen a.a.1192-1459. Available genotypes: 1a, 1b, 2b, 2c, 5, 6a |
|||
HCV NS3 1192-1456 aa Recombinant Antigen |
|||
| 00153-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS3 1192-1456aa recombinant antigen a.a.1192-1459. Available genotypes: 1a, 1b, 2b, 2c, 5, 6a |
|||
HCV NS3 1359-1456aa antigen |
|||
| 00154-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS3 1359-1456aa antigen. The protein contains immunodominant regions (1359-1456aa). available genotypes: 1a, 1b, 2b, 3, 4, 5, 6 |
|||
HCV NS3 1359-1456aa antigen |
|||
| 00154-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS3 1359-1456aa antigen. The protein contains immunodominant regions (1359-1456aa). available genotypes: 1a, 1b, 2b, 3, 4, 5, 6 |
|||
HCV NS4 mosaic recombinant antigen |
|||
| 00155-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS4 mosaic recombinant antigen a.a1691-1710, 1712-1733, 1921-1940. Genotypes available: 1, 2, 3, 5. |
|||
HCV NS4 mosaic recombinant antigen |
|||
| 00155-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS4 mosaic recombinant antigen a.a1691-1710, 1712-1733, 1921-1940. Genotypes available: 1, 2, 3, 5. |
|||
HCV NS4 1916-1947aa recombinant antigen |
|||
| 00156-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS4 1916-1947aa recombinant antigen. |
|||
HCV NS4 1916-1947aa recombinant antigen |
|||
| 00156-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS4 1916-1947aa recombinant antigen. |
|||
Amongst these, 215 DEGs had been upregulated and 242 DEGs had been downregulated within the acute injured samples in contrast with unhurt samples. The GO enrichment evaluation indicated that these DEGs had been primarily concerned in transport, the oxidation-reduction course of, the metabolic course of, steel ion binding, hydrolase exercise, and oxidoreductase exercise. The KEGG evaluation revealed that these DEGs had been considerably enriched within the PI3K-Akt signaling pathway, protein digestion and absorption pathway, and focal adhesion pathway. The hub genes together with Hnf4α, Pck1 and Timp1 had been validated by the qRT-PCR assay in NRK-49F cells within the H/R mannequin.